相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial
Alice Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
Christopher J. Edwards et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis
Robert Bissonnette et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
C. Paul et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatogy Life Quality Index (DLQI): Further Data
M. K. A. Basra et al.
DERMATOLOGY (2015)
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis
Shiu-Chung Au et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2013)
Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized study
A. B. Janagond et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet Efficacy and Safety Results From REACH, a Randomized, Placebo-Controlled, Double-blind Trial
Craig Leonardi et al.
ARCHIVES OF DERMATOLOGY (2011)
Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study
R. Bissonnette et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2011)
A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients
E. Adisen et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2009)
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: Implications for clinical practice
AA Pettey et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2003)
Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study
M Bhushan et al.
BRITISH JOURNAL OF DERMATOLOGY (2001)